Dr. Nancy U. Lin, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Harvard Medical School (1999)
- Years since graduation
- 27
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 133
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1999Medical school: Harvard Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MA license 213455
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Brigham and Women Faulkner Hospital Jamaica Plain, MA
Medical groups
- Dana-Farber Cancer Institute, Inc. (684 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 133
- Services billed
- 276
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 160 | 101 |
| Established patient office or other outpatient visit, 40-54 minutes | 96 | 56 |
| New patient office or other outpatient visit, 60-74 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Boston, MA | 16 |
| Exemestane | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 8 payments worth $7,584 in total to this clinician.
| Daiichi Sankyo Inc. | $6,295 |
|---|---|
| Stemline Therapeutics Inc. | $780 |
| Pfizer Inc. | $385 |
| AstraZeneca Pharmaceuticals LP | $124 |
| Consulting Fee | $6,954 |
|---|---|
| Food and Beverage | $509 |
| Travel and Lodging | $121 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Daiichi Sankyo Inc. Jun 18, 2025 | Consulting Fee DATROWAY · ONCOLOGY | $5,145 |
| Daiichi Sankyo Inc. May 14, 2025 | Consulting Fee DATROWAY · ONCOLOGY | $1,029 |
| Stemline Therapeutics Inc. Apr 24, 2025 | Consulting Fee Orserdu · Oncology | $780 |
| Daiichi Sankyo Inc. Nov 5, 2025 | Travel and Lodging DATROWAY · ONCOLOGY · travel to MUNICH, Germany · in-kind | $121 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $2,846,177 in research payments for these studies, mostly to the institutions running them.
- A singlearm phase ii study of sequential therapy with curative intent in de novo HER2 metastatic breast cancer the sappho study
Pfizer Inc. - A single arm open label phase 2 study of tucatinib in combination with trastuzumab deruxtecan in subjects with previously treated unresectable locallyadvanced or metastatic HER2 breast cancer
Pfizer Inc. - A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors
Hoffmann-la Roche Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.